Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/toxicity-adverse-events-and-quality-of-life-associated-with-the-TYdy8GEr0Y
- Publisher
- Karger
- Copyright
- © 2016 S. Karger AG, Basel
- ISSN
- 1661-7649
- eISSN
- 1661-7657
- DOI
- 10.1159/000447176
- Publisher site
- See Article on Publisher Site
Abstract
Objectives: Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options. The present literature review aimed to provide an overview of metastatic castration-resistant prostate cancer treatment modalities, with an emphasis on side effect profiles and general health-related QoL. Methods: PubMed was searched using the keywords metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamide, abiraterone acetate, and QoL. Conclusion: Based on the studies reviewed herein, abiraterone acetate and enzalutamide provide favorable outcomes, in terms of hematological adverse events. As enzalutamide and abiraterone acetate can be taken orally, they might have a positive effect on patient QoL.
Journal
Current Urology – Karger
Published: Jan 1, 2017
Keywords: Castration resistant prostate cancer; Docetaxel; Cabazitaxel; Enzalutamide; Abiraterone acetate; Quality of life